5 completed, 2 terminated. 3 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow amatuximab: new trials by email Literature Review of amatuximab trials Research Report on amatuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) Placebo, Amatuximab, Pemetrexed - Mesothelioma, Malignant | Phase 2 | Terminated | Morphotek | 124 | 2015-11-03 | 2020-03-17 |
| A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers Amatuximab - Mesothelioma, Pancreatic Cancer | Phase 1 | Completed | Morphotek | 6 | 2011-09-01 | 2016-09-30 |
| Amatuximab for High Mesothelin Cancers Amatuximab (MORab-009) - Carcinoma, Pancreatic Ductal, Mesothelioma | Early Phase 1 | Terminated | National Cancer Institute (NCI) | 7 | 2011-07-12 | 2019-12-17 |
| A Study of MORAb-009 in Patients With Solid Tumor MORAb-009 - Cancer, Mesothelin-positive | Phase 1 | Completed | Eisai Co., Ltd. | 17 | 2009-11-01 | 2016-01-21 |
| An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma MORAb-009 (Amatuximab), Pemetrexed, Cisplatin - Malignant Pleural Mesothelioma | Phase 2 | Completed | Morphotek | 89 | 2008-12-31 | 2022-09-22 |
| An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer MORAb-009, Placebo, Gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Morphotek | 155 | 2007-12-01 | 2015-09-09 |
| A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer MORAb-009 - Pancreatic Cancer, Mesothelioma | Phase 1 | Completed | Morphotek | 24 | 2006-05-01 | 2014-07-17 |
Carcinoma, Non-Small-Cell Lung (3) · Mesothelioma (3) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Mesothelioma, Malignant (2) · Carcinoma, Pancreatic Ductal (1) · Neoplasms (1) · Severe combined immunodeficiency with sensitivity to ionizing radiation (1)
Morphotek (5) · Eisai Co., Ltd. (1) · National Cancer Institute (NCI) (1)
United States (6) · Germany (3) · Canada (2) · Spain (2) · Australia (1) · Belgium (1) · France (1) · Italy (1) · Japan (1) · Netherlands (1) · United Kingdom (1)
Bruce Wallin, MD (1) · Chifumi Kitamura (1) · Raffit Hassan, M.D. (1) · Raffit Hassan, MD (1) · Susan C. Weil, M.D. (1)
2008 (1), 2014 (1)